Journal of Clinical Oncology, Vol 12, 1806-1813, Copyright © 1994 by American Society of Clinical Oncology
Randomized trial comparing weekly versus 3-week chemotherapy in small- cell lung cancer: a Cancer Research Campaign trial
RL Souhami, R Rudd, MC Ruiz de Elvira, L James, N Gower, PG Harper, JS Tobias, MR Partridge, AG Davison and C Trask
Departments of Oncology and Respiratory Medicine, University College London Medical School, Middlesex Hospital, United Kingdom.
PURPOSE: A randomized trial of chemotherapy, given on either a 1-week or a
3-week schedule, was performed in small-cell lung cancer (SCLC) patients.
The aim was to determine if weekly scheduling produced survival superior to
conventional treatment. PATIENTS AND METHODS: Four hundred thirty-eight
patients with SCLC with either limited disease (LD; 276 patients) or
good-prognosis extensive disease (ED; 162 patients) were randomized. Weekly
chemotherapy was 12 alternating cycles of ifosfamide/doxorubicin and
cis-platin/etoposide (PE), while 3- week treatment was six alternating
cycles of cyclophosphamide/doxorubicin/vincristine (CAV) and PE. Thoracic
irradiation was administered 3 weeks after completion of chemotherapy to LD
patients who attained a complete response (CR) or partial response (PR).
Patients were well matched for clinical characteristics and prognostic
factors. RESULTS: Overall response was the same in both arms: 82.3% (39.4%
CR) with weekly and 81.1% (36.9% CR) with 3-week treatment. The median
survival (MS) durations were 10.8 and 10.6 months for weekly and 3-week
chemotherapy, respectively. The 2-year survival rates were 11.8% and 11.7%
in the weekly and 3-week arms, respectively. Received dose-intensity (DI)
was 73.9% of projected for weekly treatment and 92.7% for 3-week treatment.
Hematologic toxicity was the major dose-limiting toxicity for the weekly
treatment. CONCLUSION: This trial excludes at 90% power a benefit of
greater than 10% for 2-year survival for weekly treatment. The received DI
was reduced to a greater extent with weekly treatment, mainly due to
hematologic toxicity.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
S. G. Spiro, L. E. James, R. M. Rudd, C. W. Trask, J. S. Tobias, M. Snee, D. Gilligan, P. A. Murray, M. C. R. de Elvira, K. M. O'Donnell, et al.
Early Compared With Late Radiotherapy in Combined Modality Treatment for Limited Disease Small-Cell Lung Cancer: A London Lung Cancer Group Multicenter Randomized Clinical Trial and Meta-Analysis
J. Clin. Oncol.,
August 20, 2006;
24(24):
3823 - 3830.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Sekine, Y. Nishiwaki, K. Noda, S. Kudoh, M. Fukuoka, K. Mori, S. Negoro, A. Yokoyama, K. Matsui, Y. Ohsaki, et al.
Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI)
Ann. Onc.,
May 1, 2003;
14(5):
709 - 714.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. H. Johnson
Management of Small Cell Lung Cancer* : Current State of the Art
Chest,
December 1, 1999;
116
(2009):
525S - 530S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Elias
Hematopoietic Stem Cell Transplantation for Small Cell Lung Cancer*
Chest,
December 1, 1999;
116
(2009):
531S - 538S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. H. Johnson and D. P. Carbone
Increased Dose-Intensity in Small-Cell Lung Cancer: A Failed Strategy?
J. Clin. Oncol.,
August 1, 1999;
17(8):
2297 - 2297.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Murray, R. B. Livingston, F. A. Shepherd, K. James, B. Zee, A. Langleben, M. Kraut, J. Bearden, J. W. Goodwin, C. Grafton, et al.
Randomized Study of CODE Versus Alternating CAV/EP for Extensive-Stage Small-Cell Lung Cancer: An Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group
J. Clin. Oncol.,
August 1, 1999;
17(8):
2300 - 2300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
